Facebook Users

Will CLLWF go up?

CLLWF Cellestis Ltd featured news, full reports, and detailed charts

Cellestis Ltd (CLLWF/CLLWF.PK) Wrap Up:

Cellestis Limited, a biotechnology company, develops, manufactures, sells, markets, and distributes medical diagnostic products worldwide. The company manufactures QuantiFERON technology products comprising QuantiFERON-CMI, QuantiFERON-TB Gold, QuantiFERON-TB Gold In-Tube, and QuantiFERON-CMV. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses of T cell lymphocytes using whole blood samples. The QuantiFERON-CMI kit is an in vitro laboratory test for the measurement of cell mediated immune responses in humans using whole blood. The QuantiFERON-CMV is an in vitro diagnostic test using a peptide cocktail simulating human cytomegalovirus proteins to stimulate cells in heparinised whole blood. The QuantiFERON-TB Gold is an in vitro diagnostic test to aid in the detection of mycobacterium tuberculosis infection. The QuantiFERON-TB Gold In-Tube enables blood handling and the blood stimulation. Cellestis Limited was incorporated in 2000 and is based in Chadstone, Australia.
www.cellestis.com
Founded in 2000

Cellestis Ltd (CLLWF:Pink OTC Markets Inc)

LAST $3.21 USD
CHANGE TODAY -0.09 -2.73%
VOLUME 0.0
As of November 19, 2009 All times are local (Market data by Reuters is delayed by at least 15 minutes).

Snapshot of Cellestis Ltd (CLLWF)

OPEN
--
PREVIOUS CLOSE
$3.21
DAY HIGH
--
DAY LOW
--
52 WEEK HIGH
11/11/09 - $3.53
52 WEEK LOW
01/27/09 - $1.05
MARKET CAP
308.2M
AVERAGE VOLUME 3 mo
308.0
DILUTED EPS TTM
--
SHARES OUTSTANDING
96.0M
CLLWF Does Not Pay Dividends
P/E TTM
NM
K = Thousands  M = Millions  B = Billions

CLLWF Top Compensated Officers

Dr. Anthony J. Radford DipCorpMan., BSc(hons), Ph.D.
Chief Executive Officer, Executive Director, ...
Age: 52
Total Annual Compensation: A$277.0K
Mr. Brian H. Manuel CA, FCIS, BComm.
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$191.0K
Mr. M. S. Boyle
General Manager of Cellestis USA
Total Annual Compensation: A$314.0K
Mr. P. B. Lebeau
General Manager of Cellestis Europe
Total Annual Compensation: A$298.0K
Dr. James S. Rothel BAppSc, MAppSc, Ph.D.
Chief Scientific Officer and Executive Direct...
Age: 51
Total Annual Compensation: A$224.0K

Executives, Board Directors

Compensation as of Fiscal Year 2009.

Key developments for Cellestis Ltd (CLLWF)

Cellestis Ltd. Announces Change of Address

Cellestis Ltd. announced that effective October 30, 2009 it has relocated its offices to: Level 1, Office Tower 2, Chadstone Centre, 1341 Dandenong Rd, Chadstone, VIC 3148. Phone: +61-3-8527-3500; Fax: +61-3-9568-6623. The company's mailing address has changed to: PO Box 169, Chadstone Centre, Chadstone, VIC 3148.

Cellestis Ltd., Annual General Meeting, Nov 16, 2009

Cellestis Ltd., Annual General Meeting, Nov 16, 2009, at 14:00 EAST-East Australian Standard GST. Location: RACV Club, Level2, 501 Bourke Street, Melbourne, Victoria, Australia. Agenda: To receive and consider the financial report of the company for the year ended June 30, 2009 and the related directors' report, directors' declaration and auditor's report; to consider remuneration report; to re-elect Mr. John Bennetts as a director; and to appoint auditor.

Cellestis Ltd. Reports Audited Consolidated and Parent Earnings Results for the Year Ended June 30, 2009

Cellestis Ltd. reported consolidated and parent earnings results for the year ended June 30, 2009. The parent company reported revenue of AUD 12,289,000 against AUD 9,149,000 for the same period a year ago. Profit from operations before tax was AUD 1,745,000 against AUD 2,315,000 for the same period a year ago. Profit before income tax was AUD 1,745,000 against AUD 2,315,000 for the same period a year ago. Profit from continuing operations and profit attributable to members of the parent entity was AUD 1,902,000 against AUD 2,315,000 for the same period a year ago. Diluted earnings per share were 1.95 cents against 2.38 cents last year. Net cash provided by operating activities was AUD 5,597,000 against AUD 961,000 last year. Investments on purchase of plant and equipment were AUD 48,000 against AUD 59,000 last year. The consolidated company reported profit attributable to members of the parent entity of AUD 8,232,000 against AUD 1,676,000 last year. Diluted earnings per share were 8.45 cents against 1.73 cents last year. Net cash provided by operating activities was AUD 6,856,000 against AUD 2,125,000 last year. Investments on purchase of plant and equipment were AUD 630,000 against AUD 133,000 last year. The substantial improvement in net profit over the previous year was largely driven by an 80% increase in revenue. The net profit also benefited from foreign exchange gains on intercompany debt repayments and amounting to AUD 1,411,000 before tax and AUD 988,000 after tax.

otc, otcbb, pinksheet, CLLWF, ob Cellestis Ltd

CLLWF Competitors

Company Last Change
No competitor information is available for CLLWF.
Market data is delayed at least 20 minutes.

Industry Analysis

Valuation CLLWF Industry Range
Price/Earnings 46.4x
Price/Sales 10.9x
Price/Book 16.9x
Price/Cash Flow 43.2x
TEV/Sales 10.4x

CLLWF

 | 

More Recent News About Cellestis Ltd

Would you like to leave a comment about Cellestis Ltd CLLWF/CLLWF.PK

Besides Cellestis Ltd there is more great information available at Realpennies.com